Blarcamesine Completed Phase 2 Trials for Alzheimer's Disease (AD) Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT02756858An Extension Study of ANAVEX2-73 in Patients With Mild to Moderate Alzheimer's Disease
NCT02244541Phase 2a Dose Finding, PK/PD and 12 Month Exploratory Efficacy Study of ANAVEX2-73 in Patients With Alzheimer's Disease